1Flther MD, Yusuf S, Kober L, et al. Longterm ACE-inhibiter therapy in patients with heart failure or left-ventricular dysfunction:a systematic overview of data from individual patients [J]. Lancet, 2000, 355:1575-1581.
2Maggioni AP, Anand I, Gottlieb SO, et al. Val-HeFT Investigators (Valsartan Heart Failure Trial).Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors [J ]. J Am Coll Cardiol, 2002, 40: 1414-1421.
3Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction - a matter of dose [J]. N Engl J Med,2003, 349(20): 1963-1965.
4Ohta K,Nakajima T,Cheah AY,et al.Elafin-overexpressing mice have improved cardiac function after myocardial infarction[J].Am J Physiol Heart Circ Physiol,2004,287(1):286-292.
5Yarbrough WM,Mukherjee R,Escobar GP,et al.Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling[J].Circulation,2003,108(14):1753-1759.
6Ernens I,Rouy D,Velot E,et al.Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils:implication of A2a receptor and cAMP/PKA/Ca2+pathway[J].Circ Res,2006,99(6):590-597.
7Tessone A,Feinberg MS,Barbash IM,et al.Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction[J].Cardiovasc Drugs Ther,2005,19(6):383-390.
8Reinhardt D,Sigusch HH,Hensse J,et al.Cardiac remodelling in end stage heart failure:up regulation of matrix metalloproteinase(MMP)irrespective of the underlying disease,and evidence for a direct inhibitory effect of ACE inhibitorson MMP[J].Heart,2002,88(5):525-530.
9Hammerer Lercher A,Neubauer E,Muller S,et al.Head to head compairson of N-terminal pro-brain natriuretic peptide,brain natriuretic peptide and N-terminal pro-atrial natriuretic pep tide in diagnosing left ventricular dysfunction[J].Clin Chim Actu,2001,310(2):193-197.
